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Immune activation is increasingly recognized as a critical element of HIV infection and pathogenesis, causing expansion of virus
founder populations at the mucosal port of entry and eventual exhaustion of cellular immune eﬀectors. HIV susceptibility is
well known to be inﬂuenced by concurrent sexually transmitted infections; however, the role of commensal vaginal microbiota is
poorly characterized. Bacterial vaginosis (BV) is a risk factor for HIV acquisition in studies worldwide; however, the etiology of BV
remains enigmatic, and the mechanisms by which BV increases HIV susceptibility are not fully deﬁned. A model of how vaginal
microbiota inﬂuences HIV transmission is considered in the context of a well-established cohort of HIV-exposed seronegative
(HESN) commercial sex workers (CSW) in Nairobi, Kenya, many of whom have increased levels of anti-inﬂammatory factors
in vaginal secretions and reduced peripheral immune activation (immune quiescence). Elucidation of the relationship between
complex microbial communities and inﬂammatory mucosal responses underlying HIV infection should be a priority for future
prevention-focussed research.
1.Introduction
Fatal opportunistic infections associated with what is now
known as the acquired immunodeﬁciency syndrome (AIDS)
wereﬁrstdescribedin1981amongyoung,previouslyhealthy
homosexual men in the United States [1]. While global
media and health authorities were focussed on stigmatized
“risk groups” in North America, largely heterosexually-
transmittedepidemicswerealreadywellestablishedthrough-
out sub-Saharan Africa by the time the human immunode-
ﬁciency virus (HIV) was discovered in 1983. A cohort-based
study of commercial sex workers (CSW) in Nairobi, Kenya
found that HIV prevalence increased from 4% to over 60%
between 1981 and 1985 [2]. Follow-up work identiﬁed a
subgroup of CSW who were never infected with HIV despite
years of exposure, one of the earliest described examples of
highly HIV-exposed seronegative (HESN) individuals in the
world [3].
HIV infection results in profound, multifactorial im-
mune dysregulation eventually leading to AIDS usually after
a period of 7–10 years. This lengthy asymptomatic pe-
riod is characteristic of the lentiviridae family of viruses
to which HIV and a wide variety of simian immunod-
eﬁciency viruses (SIV) belong. Progressive destruction of
CD4+ T helper (Th) cell populations via direct viral killing
is generally believed to explain slow disease progression;
however, recent studies in nonhuman primates have revealed
that critical events in the earliest phases of infection de-
termine SIV/HIV immunopathogenesis—a “mucosal ca-
tastrophe” [4–7].
The purposes of this review are to describe dynamics
of mucosal inﬂammation as critical determinants of HIV
transmission and AIDS pathogenesis, inﬂuences of vaginal
microbiota as the speciﬁc “microbiological context” in
which HIV transmission occurs, and how these factors may2 International Journal of Inﬂammation
interact to block HIV transmission in highly HIV-exposed
seronegative (HESN) commercial sex workers from Nairobi,
Kenya.
2.The Natureof HIVResistance
Althoughrarelyreportedinnon-humanprimateschallenged
with SIV [8], individuals in diverse groups worldwide
appear to resist HIV infection despite repeated exposure.
This variability in susceptibility to HIV infection and/or
its pathogenic consequences has been intensively studied
and found to correlate with a variety of viral, genetic,
immunological, and sociobehavioural variables; however,
the precise mechanisms of protection in HESN individuals
have not been elucidated. Study of this phenomenon is
hampered by lack of a clear terminology or deﬁnition of
who should or should not be classiﬁed as resistant to HIV,
diﬃculties in comparing groups of individuals, and the small
numbers of individuals included in these studies [9, 10].
Results from some studies indicate that cell-mediated
responses to HIV, possibly subsequent to an aborted infec-
tion, may result in protection against the establishment
of HIV systemically [11]. Late seroconversion of HESN
individuals with preexisting HIV-speciﬁc CTL responses,
possibly following a break from CSW, indicates that ongoing
exposure to CSW and/or HIV may be required to maintain
the resistant phenotype [12]. Intriguingly, HIV resistance
has also been observed in mothers and sisters of HESN
cohort members [11]. Single nucleotide polymorphisms
(SNP) in noncoding regions of the interferon regulatory
factor- (IRF-) 1 gene in HESN CSW correlate with reduced
expression of IRF-1 [13]. Among other eﬀects, reduced IRF-
1 production may lead to generalized hyporesponsiveness to
proinﬂammatory stimuli mediated by IFNγ. Generally lower
levels of basal gene transcription and downregulation of pro-
inﬂammatory cytokines in Th from HESN CSW suggest
a “quiescent” immune proﬁle [14]. Reduced activation of
Th/CTL and increased frequency of Tregs in HESN com-
pared to other HIV− individuals indicates that increased
T r e gm a yp o t e n t l yd o w n r e g u l a t eT ha c t i v a t i o nl e v e l s[ 15].
Screening of cervicovaginal lavage (CVL) protein sam-
ples from individuals in the Majengo cohort revealed
increased concentrations of the anti-inﬂammatory serine
protease inhibitor trappin-2 (also known as elaﬁn) in
CVL from HESN compared to other HIV− and HIV+
individuals[16].Recently,theepithelialoriginandsuspected
a n t i v i r a lp r o p e r t i e so ft h i sm o l e c u l ew e r ec o n ﬁ r m e d ,w i t h
studies showing direct inactivation of HIV particles during
coincubation with trappin-2 [17]. Further proteomic studies
have identiﬁed upregulation of several other antiproteases in
vaginal ﬂuid of HESN individuals, including serine protease
inhibitors and cystatin, a known anti-HIV factor [18].
Multiple and often conﬂicting immunological inﬂuences
in systemic and mucosal compartments have been investi-
gated to gain insight into the HESN phenotype. Although
little consensus has emerged, the “immune quiescence” hy-
pothesis oﬀers a plausible biological explanation for why
viral populations at points of entry do not engender pro-
ductive infections in HESN individuals.
3. Mechanisms of VaginalHIVTransmission
The eﬃciency of male-to-female sexual transmission is very
low, in the range of one productive infection for every
200–2000 exposures [19], demonstrating the formidable
physicochemical and immunological barrier of the female
genital tract (FGT) (Figure 1(a)). Semen from infected
individuals, especially those with bacterial coinfections, is
known to contain very high concentrations of free virus
as well as large numbers of infected lymphocytes and
monocytes that may directly transfer infectious virus to
vaginalepithelium,T-helper(Th)orantigen-presenting cells
such as macrophages (Mo), and Langerhans/dendritic cells
(LC/DC) at the mucosal point of entry (Figure 1(b)). The
ﬁrst barrier that the virus must cross is the mucus layer,
a dense multilayered network of glycoprotein molecules
(mucins) colonized by high concentrations of diverse micro-
organisms (vaginal microbiota). As well as creating a dense
ﬂuid gel overlying the epithelium, mucins bind covalently
to epithelial cells to create a tightly adherent layer called
the glycocalyx [20]. Both cell-free and cell-associated virus
may become trapped in these networks and subsequently
inactivated by low pH and hydrogen peroxide (H2O2)
originating from speciﬁc types of bacteria, or by epithelial-
derived proteins with antiviral properties, such as defensins
or secretory leukocyte protease inhibitor (SLPI) and related
eﬀectors [7, 21]. Even under artiﬁcial infection conditions
with a very high inoculum of pure virus, only a tiny
proportion of virions gain access to susceptible cells in the
epithelium and LP [7], with productive infection frequently
initiated by a single viral particle [22]. Changes in the
amount and consistency of excreted mucus, the proﬁle and
activity of colonizing microbiota, the amount and nature
of epithelial defence molecules due to phase of menstrual
cycle, sexual intercourse, coinfections, stress, and nutrition
are all likely to inﬂuence the likelihood that HIV can cross
this initial physical barrier.
Several mechanisms for crossing the stratiﬁed squamous
epithelium of the vagina and ectocervixor the simple colum-
nar epithelium of the endocervix and upper reproductive
tract to access target cells have been proposed; however, the
relative importance of each during infection in vivo has not
been deﬁned. Both HIV and SIV enter target cells in the FGT
primarily after binding the CD4 cell-surface glycoprotein
(receptor) and the chemokine ligands CCR5 or CXCR4 (co-
receptors) found on target cells throughout FGT epithelial
surfaces and lamina propria (LP); however, distribution of
various immune cell types has been shown to vary greatly
between individuals and anatomical sites, and is strongly
inﬂuenced by mucosal inﬂammation [23]. Normal vaginal
epitheliumischaracterizedbyintraepithelialCD8+cytotoxic
lymphocytes (CTL), relatively few Th restricted to the LP,
and low numbers of LC in basal epithelial layers. However,
greatly increased intraepithelial Th, and LC are observed in
women with chronic vaginal inﬂammation [23]. The highest
concentrations of Mo, Th, and CTL are found associated
with the “transformation zone” (TZ) of the exocervical
os (Figure 1(b)), where stratiﬁed epithelium abruptly ends
and the endocervical monolayer begins, indicating a criticalInternational Journal of Inﬂammation 3
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Figure 1: Mechanisms of vaginal HIV transmission. (a) Overview of the major anatomical features of the female genital tract (FGT). (b)
Overview of hypothetical mechanisms of HIV transmission in the female genital tract. See text for details.
position in immune control for ascending pathogens and
also increased vulnerability to HIV infection [23]. These
observations suggest distinct “immune microenvironments”
associated with diﬀerent anatomical sites within the FGT.
Although the cervix is likely to be a preferred site of entry
for HIV given higher concentrations of target cells in these
regions, especially in the TZ, large increases in numbers
of target cells in the vaginal epithelium observed during
inﬂammationincreasevulnerabilitytoHIVinfectioninthese
tissues as well.
Penetration of the epithelial layer has been shown to
happen within minutes of exposure in experiments with
non-human primates [19]. HIV binds lipid moieties such as
galactosyl cerebroside (GalC) or other receptors on vaginal
epithelial cells [24], leading to transcytosis across or produc-
tive infection of the epithelial layer [25]. Intraepithelial and
submucosal APC such as LC and DC are thought to play
an important role in viral transport to large populations of
susceptible cells in the lymphatic tissue. Terminal mannose
residues on HIV surface glycoproteins bind to related re-
ceptors or lectins such as langerin in intraepithelial LC [26].
Since LC form a tight network at the mucosal surface, and
are known to sample the luminal space with specialized cell
extensions [19], they are likely to be among the ﬁrst cells
to come into contact with HIV. Viral binding to langerin
has been found to trigger virus degradation and block cis-
infection via an endosomal pathway that is unique to LC.
In the absence of activating stimuli, LC resist infection with
HIV and transmit virus much less eﬃciently to Th when
compared to submucosal DC. However, activation of LC by
TLR stimulation and epithelial production of the cytokine
TNFα in the context of vaginal coinfections abolishes the
protective role of langerin and facilitates cis-infection and
migration of LC to lymphatic tissue [26].
Although the precise pathway travelled by HIV during
the majority of sexually transmitted infections is unknown,
it is clear that genital coinfections or other factors that (1)
increase shedding of free virus and infected cells by the
infecting partner, (2) increase permeability of the protective
mucus layer, (3) cause changes in the composition and func-
tion of vaginal microbiota, (4) disrupt the physical integrity
of the epithelial barrier, or (5) increase the abundance of
target cells at the mucosal port of entry, will increase the
likelihood that HIV will be transmitted during heterosexual
intercourse.
4. Early Tolerogenic Signalsand Mucosal
Catastrophe: A Shifting Paradigm
Once founder populations of virus have adsorbed and
penetrated target cells at the port of entry, there follows
a period of several days in which there is little or no
productive expansion of viral populations. This “eclipse
phase” (Figure 2(a)) represents a critical opportunity to
mitigate expansion of very small populations of virus in
spatially dispersed foci amid a relatively small concentration
of target cells in lamina propria (LP) relative to lymphoid
tissue [7]. Inﬂammation and immune activation near the
port of entry are likely to determine expansion or decay of
HIV founder populations [27]. If the virus reproductive rate
exceeds unity (i.e. each infected cell results in the infection
of at least one other cell), the threshold to productive
infection (the “fast phase”) is crossed on or about day seven
(Figure 2(b)). The virus-as-signal is ampliﬁed and broadcast
distallyfromtheportofentryinLPtodraininglymphnodes,
the systemic circulation, and all lymphatic tissue, rising to
peaklevelsbydaytentofourteen[7](Figure 2(c)).Asaresult
of direct viral killing and Fas/FasL-mediated apoptosis in the
presence of high concentrations of viral gp120, mucosal Th
populations, concentrated in gut-associated lymphoid tissue
(GALT), vanish almost entirely within four days [5, 7]. This4 International Journal of Inﬂammation
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Figure 2: A mucosal catastrophe. Overview of the “fast phase” of HIV infection in the days following infection, including the eclipse phase
(a), the viral broadcast phase (b), peak viremia (c), and subsequent chronic immune activation (d). See text for details.International Journal of Inﬂammation 5
massive immunological insult is not reﬂected in the systemic
circulation, where only a minority of Th reside, explaining
earlier models of gradual Th depletion in disease progression
based on measuring Th in peripheral blood only [7].
The “slow phase” of infection (Figure 2(d)) following
the initial insult is marked by chronic, generalized immune
activation, including increased activation and turnover of
Th, and increased systemic proinﬂammatory cytokines [28].
Immune activation has been found to be a better predictor
of disease progression than viral load, but whether the
virus drives immune activation or vice versa is unresolved.
Immune activation increases target cells for HIV infection
and the self-perpetuating relationship between activation
and viral replication leads to eventual clonal exhaustion of
Th memory pools, as reﬂected in rising viral loads and
declining Th counts as disease progresses [28]. Although
antiretroviraltherapycanmitigateimmunedefectsbyreduc-
ing viral replication, continued immune activation remains a
barrier to immune reconstitution following treatment [28].
In “elite controllers,” deﬁned as HIV-infected individuals
who maintain very low viral loads in the absence of treat-
ment, progressive loss of Th correlates with immune acti-
vation [28]. Therefore, regardless of virus control in later
stages of infection, chronic immune activation continues
to strongly inﬂuence disease progression, likely due to
translocation of immune-stimulating microbial products
such as lipopolysaccharide (LPS) across damaged mucosal
barriers in the gut. Consistent with this hypothesis, a recent
study has found higher LPS levels in the blood of chronically
HIV-infected people [29].
In contrast, many SIV, including SIVagm from African
green monkeys, cause no immunopathology in their natural
hosts, despite intense viral replication and massive depletion
of Th in systemic and mucosal compartments during acute
infection [30, 31]. Surprisingly, this initial insult to Th pop-
ulations does not result in enteropathy or chronic immune
activation in nonpathogenic infections, and the function
of various immune cell subsets is preserved. Although Th
numbers in peripheral blood and mucosal tissues rise in
the weeks following acute infection by both pathogenic and
nonpathogenic SIV, steep declines in the chronic phase are
only observed in pathogenic SIV infection. No increases in
Th activation or apoptosis are observed in chronic non-
pathogenic SIV infection, while activation and proliferation
of CTL occurs early and then subsides, with very little
detectable LPS in serum indicating preservation of the gut
barrier and absence of microbial translocation. Upregulation
of inﬂammatory cytokines and beta chemokines is not
observed in serum of SIVagm-infected green monkeys [31,
32]. Instead, upregulation of TGF-β stimulates expression of
FoxP3 in Th and CTL within one day of infection, leading to
high levels of immunosuppressive IL-10 at early timepoints
[32]. This early induction of the T regulatory (Treg) subset
and IL-10 may counteract immune activation signals due to
chronic infection in SIVagm-infected green monkeys.
An altered balance between Treg populations and the
related Th17 subset has also been identiﬁed in pathogenic
SIVmac infection of the pigtailed macaque, but not in
nonpathogenic SIVagm infection of the green monkey [33].
Th17 cells express IL-17 and IL-22, cytokines that have been
showntobeimportantforimmuneresponsestoextracellular
bacteria in the gut, where Th17 cells are concentrated [34].
IL-17 induces IL-8 to promote recruitment of neutrophils to
sites of bacterial infection, while IL-22 induces proliferation
of intestinal epithelial cells and repair of the mucosal barrier,
as well as stimulating epithelial production of antibacterial
defensins. Th17 cells and Treg are derived from a common
progenitor cell and their reciprocal diﬀerentiation depends
onthecytokinemilieugeneratedbyDCwithTLRstimulated
by bacterial products in peripheral tissues [33]. In humans,
the Th17 phenotype is induced in na¨ ıve T cells in the
presence of IL1β and IL-6 [35]. Interestingly, most α4β7+
cells in GALT of rhesus macaques have been shown to be
Th17 cells [36]. Therefore, preferential depletion of Th17
c e l l si np a t h o g e n i cS I V ,a sw e l la si nH I Vi n f e c t i o n[ 34], may
be due to the aﬃnity of SIV/HIV gp120 for α4β7 integrin on
gut mucosal Th, leading to permeability of mucosal barriers
in the gut, microbial translocation, and chronic immune
activation. The early upregulation of Treg in nonpathogenic
SIVinfectionmaycontributetobalancedratiosofTh17/Treg
cell populations in GALT and mitigate immune dysfunction
leading to AIDS [34].
These observations strongly suggest that the timing and
pattern of host immune responses to infection play a
critical role in determining disease outcome. Induction of
early tolerogenic responses to founder populations may
block virus propagation and broadcasting into systemic
compartments, or mitigate damage to mucosal Th popu-
lations thereby reducing immune activation resulting from
microbial translocation. Immune activation at compromised
mucosalsurfacesisacriticalcomponentofbothvulnerability
to vaginal HIV transmission and AIDS pathogenesis in the
gut; however, nothing is known about the dynamics of
normal microbiota in these contexts.
5.The MicrobiologicalContext:A Model
Vaginal microbiology is predicted to inﬂuence susceptibility
of mucosal surfaces to HIV infection via a number of
direct and indirect mechanisms (Figure 3). Genital tract
infections such as chlamydia, gonorrhea, syphilis, herpes
simplex virus (HSV), human papilloma virus (HPV), and
trichomoniasis are known to increase the risk of HIV
acquisition [37–40]. The “enigmatic” clinical entity known
asbacterialvaginosis(BV)[41,42],associatedwithincreased
susceptibility to many sexually transmitted infections, has
been shown to increase risk for HIV infection in numerous
studies from around the world [43]. BV is a frequently
asymptomatic clinical condition deﬁned by a reduction
in vaginal Lactobacillus populations and overgrowth of
anaerobic and Gram-negative organisms [42]. Increasingly
linked with negative reproductive health outcomes, such as
miscarriage,prematurebirth,postoperativeinfections,pelvic
inﬂammatory disease, and HIV infection, its etiology and
clinical course remain poorly deﬁned with a consequent lack
of eﬀective prevention and treatment strategies [41, 44, 45].
The current “gold standard” for diagnosis of BV is based
onobservationofclinicalmarkers,knownasAmsel’scriteria,6 International Journal of Inﬂammation
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Figure 3: The microbiological context of HIV resistance. Vaginal
microbiology inﬂuences susceptibility of the mucosal layer to HIV
infection in multiple interrelated ways, including (1) direct eﬀects
on viral particles or infected allogenic cells via binding, mannose
scavenging, or bacterial metabolites (acid, H2O2), (2) alteration of
quantity/viscosity/permeability of mucin network in mucus layer
via proteases, (3) stimulation of innate mucosal defence molecules
and cells via TLR stimulation, and (4) modulation of T-cell
activation and susceptibility via conditioning by TLR-stimulated
dendritic cells, macrophages, or epithelial cells.
including thin, milky discharge, high vaginal pH, presence of
“clue cells” (shed epithelial cells covered in Gram-negative
bacteria), and amine (“ﬁshy”) odour [46]. In the laboratory
setting,moststudiesrelyonscoringproﬁleofmicrobialtypes
in Gram-stained vaginal swabsmears [47]. These systemsare
based on the relative abundance of Lactobacillus morpho-
types (short to long, straight-sided rods) compared to BV
bacteria morphotypes (Gram-negative/variable coccobacilli
a n dc u r v e dr o d s ) .
Quantitative bacteriology and microbial ecology are of
particular concern in understanding BV, which is deﬁned by
changes in levels of total bacteria and alterations in abun-
dance of bacterial subpopulations, rather than the presence
of a speciﬁc pathogen [44]. For example, BV-associated
bacteria such as Gardnerella, Mobiluncus, Atopobium, and
Mycoplasma species are routinely isolated from women
without BV [45]. Simultaneous isolation of Mycoplasma,
Gardnerella, and anaerobes, described as a “pathologic core,”
combined with failure to isolate Lactobacillus in a vaginal
sample, has been found to be strongly associated with BV
[48]. Despite a general lack of external signs of inﬂammation
in BV (as indicated by the -osis suﬃx signifying overgrowth,
rather than the -itis suﬃx signifying inﬂammation) [49],
many studies associate BV with increased proinﬂammatory
signalling via TLR stimulation [50–52]. BV is characterized
by an increase in the overall bacterial load in the vagina,
with possible implications for TLR stimulation and immune
activation. The presence of various proteolytic enzymes
during BV demonstrate the importance of mucin lysis as
a source of energy for the bacterial consortium [53], and
may also explain nutritional synergies observed in culture-
based experiments with BV bacteria [54]. Enzymes such as
sialidase and prolidase have been shown to impair innate
and adaptive immune eﬀectors in the vagina, including
cytokines, immunoglobulins, and cellular receptors, and are
likely to explain lack of overt signs of inﬂammation despite
local production of pro-inﬂammatory signals during BV
[55]. Thinning of the vaginal mucus layer may also increase
opportunities for HIV to access target cells in underlying
mucosa.
Given a preeminent ecological position in the vaginal
environment [56], colonization of the female genital tract
by Lactobacillus species is increasingly recognized as critical
for overall vaginal health and resistance to infection by
bacterial and viral pathogens, including HIV [57]. Under the
inﬂuence of estrogen, vaginal epithelial cells store glycogen,
which is hydrolysed to glucose and metabolized by vaginal
bacteria [58]. Excreted lactate, especially by Lactobacillus
species, reduces the overall pH of the vaginal lumen to
“normal”levels,intherangeof3.9to4.5[59,60].Alongwith
eﬀectors such as H2O2 and bacteriocins, acid production
by Lactobacillus is believed to discourage overgrowth of
other bacterial genera including Streptococcus, Gardnerella,
Bacteroides, and Mycoplasma [61]. H2O2 produced by a
Lactobacillus strain has been shown to inactivate HIV in
vitro [62]. Production of acid and H2O2 may be synergistic,
since bacterial H2O2 is more likely to remain stable at
lower pH in vitro [63]. The ability of Lactobacillus to
produce acid from mannose scavenged as a carbon source
has also been hypothesized to block HIV infection through
digestion of mannosylated residues on viral glycoproteins
[64]. Interestingly, two promising molecules currently being
studiedaspotentialtopicalagentsforblocking HIVinfection
(microbicides) also bind mannose residues on the viral
surface [65, 66].
Absence of culturable H2O2-producing Lactobacillus has
been shown to be an important contributing factor in
elevated risk for cervicitis observed in those with BV
[67]. This ﬁnding conﬁrms that BV-related organisms are
associatedwithanelevatedriskofgenitaltractinﬂammation,
the converse of which may be a non/anti-inﬂammatory
role for Lactobacillus organisms. The possibility of anti-
inﬂammatoryeﬀectsbyLactobacillusorganismsinthevagina
is all but unexplored, although several studies concerning
the gut epithelium indicate induction of epithelial defence
molecules, anti-inﬂammatory signalling, and increased Treg
by speciﬁc strains of Lactobacillus [55, 68–70].
We recently conducted the ﬁrst study to address BV
and Lactobacillus colonization speciﬁcally as possible factors
contributingtoHIVresistanceinhighlyexposedcommercial
sex workers fron Nairobi [71]. Compared to other HIV−
individuals, HESN in the Majengo cohort were just as likely
to be diagnosed with BV and had similar vaginal pH in a
cross-sectional study, a ﬁnding conﬁrmed by retrospective
analysis of BV diagnoses over several years in nearly 1,000
individuals [71]. Ultradeep molecular characterization of
vaginal microbiota also revealed few diﬀerences in species
distribution between HESN and other HIV− individuals
[72]; however, neither study was conclusive. BV is known
to induce a pro-inﬂammatory environment and create
vulnerability to HIV, so the ability of an individual toInternational Journal of Inﬂammation 7
modulate some aspect of the inﬂammatory process related
to the BV cycle may determine her ability to block viral
infection. Longitudinal studies examining dynamics of vagi-
nal microbiota and mucosal responses over time will be
necessaryinordertodeﬁnitivelyaddressthepotentialimpact
of vaginal microbiology on HIV resistance in the Majengo
cohort.
6. Conclusions
The immune activation hypothesis of HIV pathogenesis
suggests that multiple factors may contribute to reduced
viral broadcast at the mucosal port of entry, either blocking
productive infection entirely or limiting damage to lym-
phoid tissue subsequent to peak viremia. Therefore, these
phenomena may be seen as being part of a continuum of
HIV resistance [10]. HESN CSW in the Majengo cohort
are among the most striking and well-studied examples
of HIV resistance worldwide. Ongoing characterization
of this group has revealed many immunogenetic factors
that may contribute to relative resistance in a subgroup
of CSW, including recent ﬁndings indicating a role for
reduced T-cell activation or “immune quiescence.” Mucosal
studies have revealed the possibility that HESN CSW may
have increased anti-inﬂammatory factors in mucosal ﬂuids,
mirroring reduced immune activation in peripheral blood.
Together, these studies suggest a uniﬁed set of factors in
HESN women that reduce susceptibility of target cells in vivo
or hamper viral expansion from the mucosal port of entry.
Although the vaginal microbiota has so far not been
found to play a critical role in HIV resistance, the purpose of
this review has been to clarify the role that mucosal inﬂam-
mation and microbiological dynamics play in the earliest
stagesofHIVdisease.Innaturalinfections,thebestpredictor
of immunodeﬁciency and disease is not lentiviral replication
within the host but T-cell activation and activation-induced
cell death leading to depletion of critical cell populations.
Early immunosuppressive signals and upregulation of T-
regulatorycellswithin24hoursofinfectionarecharacteristic
of nonpathogenic infections, despite subsequent intense
viral replication and initial depletion of CD4 in blood and
lymphoid tissue in both pathogenic and nonpathogenic
infections, while CSW who resist HIV infection entirely
for long periods appear to have reduced levels of T cell
activation and increased anti-inﬂammatory molecules in
vaginal secretions.
These ﬁndings indicate that modulating immune activa-
tion, rather than directly interfering with virus, may be an
alternative strategy for stopping HIV infection or mitigating
pathogenesis. Whether the purposeful application of live
microorganisms (probiotics) might be beneﬁcial for these
purposes has only begun to explored [73], but similar prin-
ciples guide the development of HIV microbicides, deﬁned
as topical agents applied vaginally to block HIV transmission
[74]. Few studies have comprehensively assessed the impact
of microbicides on vaginal microbiota, examining only very
limited culture-based parameters. In-depth analysis of the
microbiological context is likely to be critical for assessment
of candidate microbicides on composition, structure, and
function of vaginal microbial communities. A concerted
eﬀort to generate detailed microbiological proﬁles and
link this information to mucosal immune parameters will
inform upcoming clinical trials for “second generation”
microbicides, including probiotics, as potentially eﬀective
tools for HIV prevention.
Central questions of HIV prevention-related research
in coming years might be how do microbiological and
host factors interact with each other as part of the normal
functioning of mucosal surfaces exposed to a wide variety
of endogenous and exogenous stimuli? How do these
interactions inﬂuence the likelihood that HIV introduced at
the interface of host and microbiota will cross formidable
physicochemical barriers and irreversibly alter host immune
function? Many challenges remain to adequately deﬁne
vaginal microbial community dynamics across individuals
and over time.
Funding
Funding was provided by National Institutes of Health, Bill
& Melinda Gates Foundation, Canadian Institutes of Health
Research (CIHR).
Acknowledgment
The authors would like to thank the women of the Majengo
cohort whose ongoing commitment has made this work
possible, as well as all the scientists, laboratory, clinical and
administrative personnel in Nairobi and Winnipeg.
References
[1] M. S. Gottlieb, R. Schroﬀ, and H. M. Schanker, “Pneumocystis
carinii pneumonia and mucosal candidiasis in previously
healthy homosexual men. Evidence of a new acquired cellular
immunodeﬁciency,” New England Journal of Medicine, vol.
305, no. 24, pp. 1425–1431, 1981.
[ 2 ]J .K .K r e i s s ,D .K o e c h ,a n dF .A .P l u m m e r ,“ A I D Sv i r u s
infectioninNairobiprostitutes.SpreadoftheepidemictoEast
Africa,” New England Journal of Medicine, vol. 314, no. 7, pp.
414–418, 1986.
[3] K. R. Fowke, N. J. D. Nagelkerke, J. Kimani et al., “Resistance
toHIV-1infectionamongpersistentlyseronegativeprostitutes
in Nairobi, Kenya,” Lancet, vol. 348, no. 9038, pp. 1347–1351,
1996.
[4] J. M. Brenchley and D. C. Douek, “The mucosal barrier and
immune activation in HIV pathogenesis,” Current Opinion in
HIV and AIDS, vol. 3, no. 3, pp. 356–361, 2008.
[5] J. M. Brenchley, D. A. Price, and D. C. Douek, “HIV disease:
fallout from a mucosal catastrophe?” Nature Immunology, vol.
7, no. 3, pp. 235–239, 2006.
[6] A.T.Haase,“Thepathogenesisofsexualmucosaltransmission
and early stages of infection: obstacles and a narrow window
of opportunity for prevention,” AIDS, vol. 15, supplement 1,
pp. S10–S11, 2001.
[7] A. T. Haase, “Perils at mucosal front lines for HIV and SIV
and their hosts,” Nature Reviews Immunology, vol. 5, no. 10,
pp. 783–792, 2005.8 International Journal of Inﬂammation
[8] B. Peng, R. Voltan, L. Lim et al., “Rhesus macaque resistance
to mucosal simian immunodeﬁciency virus infection is asso-
ciated with a postentry block in viral replication,” Journal of
Virology, vol. 76, no. 12, pp. 6016–6026, 2002.
[9] R. E. Horton, P. J. McLaren, K. Fowke, J. Kimani, and T. B.
Ball, “Cohorts for the study of HIV-1-exposed but uninfected
individuals: beneﬁts and limitations,” J o u r n a lo fI n f e c t i o u s
Diseases, vol. 202, supplement 3, pp. S377–S381, 2010.
[ 1 0 ]M .M a r m o r ,K .H e r t z m a r k ,S .M .T h o m a s ,P .N .H a l k i t i s ,a n d
M. Vogler, “Resistance to HIV Infection,” J o u r n a lo fU r b a n
Health, vol. 83, no. 1, pp. 5–17, 2006.
[11] F. A. Plummer, T. B. Ball, J. Kimani, and K. R. Fowke, “Re-
sistance to HIV-1 infection among highly exposed sex work-
ers in Nairobi: what mediates protection and why does it
develop?” Immunology Letters, vol. 66, no. 1–3, pp. 27–34,
1999.
[12] R. Kaul, S. L. Rowland-Jones, J. Kimani et al., “Late sero-
conversion in HIV-resistant Nairobi prostitutes despite pre-
existing HIV-speciﬁc CD8+ responses,” Journal of Clinical
Investigation, vol. 107, no. 3, pp. 341–349, 2001.
[13] T. B. Ball, H. Ji, J. Kimani et al., “Polymorphisms in IRF-1
associatedwithresistancetoHIV-1infectioninhighlyexposed
uninfected Kenyan sex workers,” AIDS,v o l .2 1 ,n o .9 ,p p .
1091–1101, 2007.
[14] P. J. McLaren, T. B. Ball, C. Wachihi et al., “HIV-exposed
seronegative commercial sex workers show a quiescent pheno-
type in the CD4+ T cell compartment and reduced expression
of HIV-dependent host factors,” Journal of Infectious Diseases,
vol. 202, no. 3, pp. S339–S344, 2010.
[15] C. M. Card, P. J. McLaren, C. Wachihi, J. Kimani, F. A.
Plummer, and K. R. Fowke, “Decreased immune activation in
resistancetoHIV-1infectionisassociatedwithanelevatedfre-
quency ofCD4+CD25+FOXP3+ RegulatoryTCells,”Journalof
Infectious Diseases, vol. 199, no. 9, pp. 1318–1322, 2009.
[16] S. M. Iqbal, T. B. Ball, P. Levinson et al., “Elevated
elaﬁn/trappin-2 in the female genital tract is associated with
protection against HIV acquisition,” AIDS, vol. 23, no. 13, pp.
1669–1677, 2009.
[17] M. Ghosh, Z. Shen, J. V. Fahey, S. Cu-Uvin, K. Mayer, and
C. R. Wira, “Trappin-2/Elaﬁn: a novel innate anti-human
immunodeﬁciency virus-1 molecule of the human female
reproductive tract,” Immunology, vol. 129, no. 2, pp. 207–219,
2010.
[18] A. Burgener, J. Boutilier, C. Wachihi et al., “Identiﬁcation
of diﬀerentially expressed proteins in the cervical mucosa of
HIV-1-resistant sex workers,” Journal of Proteome Research,
vol. 7, no. 10, pp. 4446–4454, 2008.
[19] F. Hladik and M. J. McElrath, “Setting the stage: host invasion
by HIV,” Nature Reviews Immunology, vol. 8, no. 6, pp. 447–
457, 2008.
[20] M. Wilson, Microbial Inhabitants of Humans: Their Ecology
a n dR o l ei nH e a l t ha n dD i s e a s e , Cambridge University Press,
Cambridge, UK, 2005.
[21] S. S. Olmsted, K. V. Khanna, E. M. Ng et al., “Low pH immo-
bilizes and kills human leukocytes and prevents transmission
of cell-associated HIV in a mouse model,” BMC Infectious
Diseases, vol. 5, article no. 79, 2005.
[22] J. A. Levy, “HIV pathogenesis: 25 years of progress and
persistent challenges,” AIDS, vol. 23, no. 2, pp. 147–160, 2009.
[23] J. Pudney, A. J. Quayle, and D. J. Anderson, “Immunological
microenvironments in the human vagina and cervix: medi-
ators of cellular immunity are concentrated in the cervical
transformation zone,” Biology of Reproduction, vol. 73, no. 6,
pp. 1253–1263, 2005.
[24] Y. Furuta, K. Eriksson, B. Svennerholm et al., “Infection of
vaginal and colonic epithelial cells by the human immunode-
ﬁciency virus type 1 is neutralized by antibodies raised against
conserved epitopes in the envelope glycoprotein gp120,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 91, no. 26, pp. 12559–12563, 1994.
[25] J. Zheng, Y. Xie, R. Campbell et al., “gp120-independent
HIV infection of cells derived from the female reproductive
tract,brain,andcolon,”JournalofAcquiredImmuneDeﬁciency
Syndromes, vol. 43, no. 2, pp. 127–136, 2006.
[ 2 6 ]M .A .W .P .D eJ o n ga n dT .B .H .G e i j t e n b e e k ,“ H u m a ni m -
munodeﬁciency virus-1 acquisition in genital mucosa: langer-
hanscellsaskey-players,”JournalofInternalMedicine,vol.265,
no. 1, pp. 18–28, 2009.
[27] R. Kaul, C. Pettengell, P. M. Sheth et al., “The genital tract
immune milieu: an important determinant of HIV suscep-
tibility and secondary transmission,” Journal of Reproductive
Immunology, vol. 77, no. 1, pp. 32–40, 2008.
[28] D. C. Douek, M. Roederer, and R. A. Koup, “Emerging
conceptsintheimmunopathogenesisofAIDS,”Annual Review
of Medicine, vol. 60, pp. 471–484, 2009.
[29] J. M. Brenchley, D. A. Price, T. W. Schacker et al., “Microbial
translocation is a cause of systemic immune activation in
chronic HIV infection,” Nature Medicine, vol. 12, no. 12, pp.
1365–1371, 2006.
[30] A. S. Liovat, B. Jacquelin, M. J. Ploquin, F. Barr´ e-Sinoussi, and
M. C. M¨ uller-Trutwin, “African non human primates infected
by SIV—why don’t they get sick? Lessons from studies on the
early phase of non-pathogenic SIV infection,” Current HIV
Research, vol. 7, no. 1, pp. 39–50, 2009.
[31] I. Pandrea, D. L. Sodora, G. Silvestri, and C. Apetrei, “Into
the wild: simian immunodeﬁciency virus (SIV) infection in
natural hosts,” Trends in Immunology, vol. 29, no. 9, pp. 419–
428, 2008.
[32] C. Kornfeld, M. J. Y. Ploquin, I. Pandrea et al., “Antiinﬂam-
matory proﬁles during primary SIV infection in African green
monkeys areassociated withprotectionagainst AIDS,” Journal
of Clinical Investigation, vol. 115, no. 4, pp. 1082–1091, 2005.
[33] D. Favre, S. Lederer, B. Kanwar et al., “Critical loss of the
balance between Th17 and T regulatory cell populations in
pathogenicSIVinfection,”PLoSPathogens,vol.5,no .2,Article
ID e1000295, 2009.
[34] J. M. Brenchley, M. Paiardini, K. S. Knox et al., “Diﬀerential
Th17 CD4 T-cell depletion in pathogenic and nonpathogenic
lentiviral infections,” Blood, vol. 112, no. 7, pp. 2826–2835,
2008.
[35] E. V. Acosta-Rodriguez, G. Napolitani, A. Lanzavecchia, and F.
Sallusto, “Interleukins 1β and 6 but not transforming growth
factor-β are essential for the diﬀerentiation of interleukin 17-
producing human T helper cells,” Nature Immunology, vol. 8,
no. 9, pp. 942–949, 2007.
[36] M. Kader, X. Wang, M. Piatak et al., “α4+β7hiCD4+ memory
T cells harbor most Th-17 cells and are preferentially infected
during acute SIV infection,” Mucosal Immunology, vol. 2, no.
5, pp. 439–449, 2009.
[37] K. T. Bernstein, J. L. Marcus, G. Nieri, S. S. Philip, and J.
D. Klausner, “Rectal gonorrhea and chlamydia reinfection is
associated with increased risk of HIV seroconversion,” Journal
of Acquired Immune Deﬁciency Syndromes,v o l .5 3 ,n o .4 ,p p .
537–543, 2010.
[38] D. T. Fleming and J. N. Wasserheit, “From epidemiological
synergy to public health policy and practice: the contributionInternational Journal of Inﬂammation 9
of other sexually transmitted diseases to sexual transmission
of HIV infection,” Sexually Transmitted Infections, vol. 75, no.
1, pp. 3–17, 1999.
[39] C. T. Kane, S. Diawara, H. D. Ndiaye et al., “Concentrated and
linked epidemics of both HSV-2 and HIV-1/HIV-2 infections
in Senegal: public health impacts of the spread of HIV,”
International Journal of STD and AIDS, vol. 20, no. 11, pp.
793–796, 2009.
[40] S. C. Shaﬁr, F. J. Sorvillo, and L. Smith, “Current issues and
considerations regarding trichomoniasis and human immun-
odeﬁciency virus in African-Americans,” Clinical Microbiology
Reviews, vol. 22, no. 1, pp. 37–45, 2009.
[41] P. G. Larsson, M. Bergstr¨ o m ,U .F o r s u m ,B .J a c o b s s o n ,A .
Strand,andP.W¨ olner-Hanssen,“Bacterialvaginosistransmis-
sion, role in genital tract infection and pregnancy outcome: an
enigma,” APMIS, vol. 113, no. 4, pp. 233–245, 2005.
[42] L. Westrom, G. Evaldson, and K. K. Holmes, “Taxonomy of
vaginosis: bacterial vaginosis—a deﬁnition,” Scandinavian
Journal of Urology and Nephrology Supplement, vol. 86, pp.
259–264, 1984.
[43] J. Atashili, C. Poole, P. M. Ndumbe, A. A. Adimora, and J.
S. Smith, “Bacterial vaginosis and HIV acquisition: a meta-
analysis of published studies,” AIDS, vol. 22, no. 12, pp. 1493–
1501, 2008.
[ 4 4 ]U .F o r s u m ,A .H a l l ´ en, and P. G. Larsson, “Bacterial vag-
inosis—a laboratory and clinical diagnostics enigma: review
article II,” APMIS, vol. 113, no. 3, pp. 153–161, 2005.
[45] U. Forsum, E. Holst, P. G. Larsson, A. Vasquez, T. Jakobsson,
and I. Mattsby-Baltzer, “Bacterial vaginosis—a microbiologi-
cal and immunological enigma,” APMIS, vol. 113, no. 2, pp.
81–90, 2005.
[46] R. Amsel, P. A. Totten, and C. A. Spiegel, “Nonspeciﬁc
vaginitis. Diagnostic criteria and microbial and epidemiologic
associations,” American Journal of Medicine, vol. 74, no. 1, pp.
14–22, 1983.
[47] R. P. Nugent, M. A. Krohn, and S. L. Hillier, “Reliability of
diagnosing bacterial vaginosis is improved by a standardized
method of gram stain interpretation,” Journal of Clinical
Microbiology, vol. 29, no. 2, pp. 297–301, 1991.
[48] P. Thorsen, I. P. Jensen, B. Jeune et al., “Few microorganisms
associated with bacterial vaginosis may constitute the patho-
logic core: a population-based microbiologic study among
3596 pregnant women,” American Journal of Obstetrics and
Gynecology, vol. 178, no. 3, pp. 580–587, 1998.
[49] E.J.Huth,“Stylenotes:bacterialvaginosisorvaginalbacterio-
sis?” Annals of Internal Medicine, vol. 111, no. 7, pp. 553–554,
1989.
[50] P. Losikoﬀ, R. Fichorova, B. Snyder et al., “Genital tract
interleukin-8 but not interleukin-1β or interleukin-6 concen-
tration is associated with bacterial vaginosis and its clearance
in HIV-infected and HIV-uninfected women,” Infectious Dis-
eases in Obstetrics and Gynecology, vol. 2007, Article ID 92307,
p. 6, 2007.
[51] D. Mares, J. A. Simoes, R. M. Novak, and G. T. Spear, “TLR2-
mediated cell stimulation in bacterial vaginosis,” Journal of
Reproductive Immunology, vol. 77, no. 1, pp. 91–99, 2008.
[52] C. M. Mitchell, J. Balkus, K. J. Agnew et al., “Bacterial vag-
inosis, not HIV, is primarily responsible for increased vaginal
concentrations of proinﬂammatory cytokines,” AIDS Research
and Human Retroviruses, vol. 24, no. 5, pp. 667–671, 2008.
[53] A. M. Roberton, R. Wiggins, P. J. Horner et al., “A novel
bacterial mucinase, glycosulfatase, is associated with bacterial
vaginosis,” Journal of Clinical Microbiology, vol. 43, no. 11, pp.
5504–5508, 2005.
[54] V. Pybus and A. B. Onderdonk, “Evidence for a commensal,
symbiotic relationship between Gardnerella vaginalis and
Prevotella bivia involving ammonia: potential signiﬁcance for
bacterial vaginosis,” Journal of Infectious Diseases, vol. 175, no.
2, pp. 406–413, 1997.
[55] S. Cauci, S. Guaschino, S. Driussi, D. De Santo, P. Lanzafame,
and F. Quadrifoglio, “Correlation of local interleukin-8 with
immunoglobulin A against Gardnerella vaginalis hemolysin
andwithprolidaseandsialidaselevelsinwomenwithbacterial
vaginosis,” Journal of Infectious Diseases, vol. 185, no. 11, pp.
1614–1620, 2002.
[56] P. Hay, “Life in the littoral zone: lactobacilli losing the plot,”
Sexually Transmitted Infections, vol. 81, no. 2, pp. 100–102,
2005.
[57] K. C. Anukam, E. O. Osazuwa, I. Ahonkhai, and G. Reid,
“Lactobacillus vaginal microbiota of women attending a
reproductive health care service in Benin City, Nigeria,”
Sexually Transmitted Diseases, vol. 33, no. 1, pp. 59–62, 2006.
[58] S. L. Hillier, “The vaginal microbial ecosystem and resistance
to HIV,” AIDS Research and Human Retroviruses, vol. 14,
supplement 1, pp. S17–S21, 1998.
[59] E. R. Boskey, R. A. Cone, K. J. Whaley, and T. R. Moench,
“Origins of vaginal acidity: high D/L lactate ratio is consistent
withbacteriabeingtheprimarysource,”HumanReproduction,
vol. 16, no. 9, pp. 1809–1813, 2001.
[ 6 0 ]E .R .B o s k e y ,K .M .T e l s c h ,K .J .W h a l e y ,T .R .M o e n c h ,a n d
R. A. Cone, “Acid production by vaginal ﬂora in vitro is
consistent with the rate and extent of vaginal acidiﬁcation,”
Infection and Immunity, vol. 67, no. 10, pp. 5170–5175, 1999.
[61] P.DanielJohannesR¨ onnqvist,U.BirgittaForsgren-Brusk,and
E. Elisabeth Grahn-H˚ akansson, “Lactobacilli in the female
genital tract in relation to other genital microbes and vaginal
pH,” Acta Obstetricia et Gynecologica Scandinavica, vol. 85, no.
6, pp. 726–735, 2006.
[62] S. J. Klebanoﬀ and R. W. Coombs, “Viricidal eﬀect of
Lactobacillus acidophilus on human immunodeﬁciency virus
type 1: possible role in heterosexual transmission,” Journal of
Experimental Medicine, vol. 174, no. 1, pp. 289–292, 1991.
[63] E.A.FontaineandD.Taylor-Robinson,“Comparisonofquan-
titative and qualitative methods of detecting hydrogen perox-
ide produced by human vaginal strains of lactobacilli,” Journal
of Applied Bacteriology, vol. 69, no. 3, pp. 326–331, 1990.
[64] L. Tao, S. Pavlova, J. Anzinger et al., “Fighting HIV with its
natural enemy: mannose-speciﬁc capture of HIV by Lac-
tobacillus,” Beneﬁcial Microbes Conference, Poster Abstract
#5B, 2005, http://www.asm.org/.
[65] V. Buﬀa, D. Stieh, N. Mamhood, Q. Hu, P. Fletcher, and R. J.
Shattock, “Cyanovirin-N potently inhibits human immunod-
eﬁciency virus type 1 infection in cellular and cervical explant
models,” Journal of General Virology, vol. 90, no. 1, pp. 234–
243, 2009.
[66] B. R. O’Keefe, F. Vojdani, V. Buﬀa et al., “Scaleable manu-
facture of HIV-1 entry inhibitor griﬃthsin and validation of
its safety and eﬃcacy as a topical microbicide component,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 106, no. 15, pp. 6099–6104, 2009.
[67] J. M. Marrazzo, H. C. Wiesenfeld, P. J. Murray et al., “Risk
factors for cervicitis among women with bacterial vaginosis,”
Journal of Infectious Diseases, vol. 193, no. 5, pp. 617–624,
2006.10 International Journal of Inﬂammation
[68] H. Braat, J. van den Brande, E. Van Tol, D. Hommes, M. Pep-
pelenbosch, and S. Van Deventer, “Lactobacillus rhamnosus
induces peripheral hyporesponsiveness in stimulated CD4+
T cells via modulation of dendritic cell function,” American
Journal of Clinical Nutrition, vol. 80, no. 6, pp. 1618–1625,
2004.
[69] P. W. Lin, L. E. S. Myers, L. Ray et al., “Lactobacillus rham-
nosus blocks inﬂammatory signaling in vivo via reactive
oxygen species generation,” Free Radical Biology and Medicine,
vol. 47, no. 8, pp. 1205–1211, 2009.
[70] M. T. Tien, S. E. Girardin, B. Regnault et al., “Anti-
inﬂammatory eﬀect of Lactobacillus casei on Shigella-infected
human intestinal epithelial cells,” Journal of Immunology, vol.
176, no. 2, pp. 1228–1237, 2006.
[71] J. J. Schellenberg, C. M. Card, T. B. Ball et al., “Bacterial
vaginosis, HIV serostatus and T-cell subset distribution in a
cohort of East African commercial sex workers: retrospective
analysis,” AIDS, vol. 26, no. 3, pp. 387–393, 2012.
[72] J. J. Schellenberg, M. G. Links, J. E. Hill et al., “Molecular
deﬁnitionofvaginalmicrobiotaineastafricancommercialsex
workers,” Applied and Environmental Microbiology, vol. 77, no.
12, pp. 4066–4074, 2011.
[73] R. Hummelen, A. P. Vos, B. Van’T Land, K. Van Norren, and
G. Reid, “Altered host-microbe interaction in HIV: a target for
intervention with pro- and prebiotics,” International Reviews
of Immunology, vol. 29, no. 5, pp. 485–513, 2010.
[74] I. McGowan, “Microbicides for HIV prevention: reality or
hope?” Current Opinion in Infectious Diseases, vol. 23, no. 1,
pp. 26–31, 2010.